Insider Transactions in Q1 2024 at Aquestive Therapeutics, Inc. (AQST)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.83%
|
$300,000
$6.0 P/Share
|
|
Mar 10
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,132
-0.47%
|
$4,528
$4.88 P/Share
|
|
Mar 10
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-0.65%
|
$6,748
$4.88 P/Share
|
|
Mar 09
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,895
-0.57%
|
$23,580
$4.88 P/Share
|
|
Mar 09
2024
|
Cassie Jung Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,300
-3.36%
|
$33,200
$4.88 P/Share
|
|
Mar 09
2024
|
Stephen Wargacki Chief Science Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,269
-4.16%
|
$45,076
$4.88 P/Share
|
|
Mar 09
2024
|
A Ernest Toth Jr SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,705
-4.5%
|
$46,820
$4.88 P/Share
|
|
Mar 09
2024
|
Lori J Braender SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,530
-3.25%
|
$42,120
$4.88 P/Share
|
|
Mar 09
2024
|
Peter E. Boyd See Remark |
SELL
Payment of exercise price or tax liability
|
Direct |
8,370
-3.4%
|
$33,480
$4.88 P/Share
|
|
Mar 09
2024
|
Daniel Barber President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,938
-4.3%
|
$151,752
$4.88 P/Share
|
|
Mar 08
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.35%
|
$125,000
$5.19 P/Share
|
|
Mar 07
2024
|
Stephen Wargacki Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+29.34%
|
-
|
|
Mar 07
2024
|
Peter E. Boyd See Remark |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+25.96%
|
-
|
|
Mar 07
2024
|
Cassie Jung Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,250
+29.06%
|
-
|
|
Mar 07
2024
|
Daniel Barber President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
242,600
+21.55%
|
-
|
|
Mar 07
2024
|
Carl N Kraus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+30.0%
|
-
|
|
Mar 07
2024
|
Alexander Mark Schobel Chief Innovation/Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+7.19%
|
-
|
|
Mar 07
2024
|
A Ernest Toth Jr SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+31.58%
|
-
|
|
Mar 07
2024
|
Lori J Braender SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+29.43%
|
-
|